We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA hit Blaine Labs with a lengthy Form 483 for a host of violations at its Santa Fe Springs, CA, facility, including repeated quality unit failures. Read More
The facility lacked written procedures for stability studies, deviation investigations, out-of-specification investigations and product release. Read More
The FDA issued a warning letter to an active pharmaceutical ingredient and over-the-counter drug manufacturer in the Chinese port city of Guangzhou for releasing products without performing microbial tests. Read More
The FDA issued a 14-observation Form 483 to Irvine, California drugmaker Stason Pharmaceuticals for inadequate testing and other quality failures. Read More
The FDA hit JHS Svendgaard Hygiene Products with a warning letter for serious GMP failures at its drug manufacturing facility in Himachal Pradesh, India. Read More